EP0890645A2 - Sialyltransferase and DNA encoding the same - Google Patents

Sialyltransferase and DNA encoding the same Download PDF

Info

Publication number
EP0890645A2
EP0890645A2 EP98305422A EP98305422A EP0890645A2 EP 0890645 A2 EP0890645 A2 EP 0890645A2 EP 98305422 A EP98305422 A EP 98305422A EP 98305422 A EP98305422 A EP 98305422A EP 0890645 A2 EP0890645 A2 EP 0890645A2
Authority
EP
European Patent Office
Prior art keywords
sialyltransferase
amino acid
sialic acid
seq
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98305422A
Other languages
German (de)
French (fr)
Other versions
EP0890645A3 (en
Inventor
Masaki Saito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seikagaku Corp
Original Assignee
Seikagaku Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seikagaku Corp filed Critical Seikagaku Corp
Publication of EP0890645A2 publication Critical patent/EP0890645A2/en
Publication of EP0890645A3 publication Critical patent/EP0890645A3/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Definitions

  • the present invention relates to a sialyltransferase and to a DNA encoding the same. More particularly, the present invention relates to an enzyme which synthesizes ganglioside G M3 by transferring sialic acid to a galactose residue of lactosylceramide and to a DNA encoding the enzyme.
  • Human myelogenous leukemia cell line HL-60 which is a cell line that has acquired the ability of infinite proliferation as a result of tumorigenic transformation, is used generally and widely as a model for leukemia cells (Collins, S.J. Gallo, R.C., and Gallagher, R.E., Nature (London), 270, 347-349 (1977); Collins, S.J., Blood, 70, 1223 (1987)).
  • the cell line does not differentiate even after continued cultivation and continues to proliferate while it remains as undifferentiated cells.
  • phorbol ester which is widely used as a differentiation inducer, the cell line stops the proliferation of cells and takes an appearance similar to that of monocytes or macrophages.
  • G M3 itself has an activity of inducing differentiation (Nojiri, H., Takaku, F., Miura, Y., and Saito, M., Proc. Natl. Acad. Sci. U.S.A., 83, 782-786 (1986)), and that chemically synthesized G M3 also induces differentiation (Sugimoto, M. and Ogawa, T., Glycoconj.
  • gangliosides ganglio-series gangliosides
  • G M3 ganglio-series gangliosides
  • ganglioside G M3 itself participates in the proliferation/differentiation of cells and tissues and it is suggested that the ganglioside G M3 is a precursor for a group of higher gangliosides having various functions in vertebrates.
  • G M3 has been considered to be synthesized from lactosylceramide by transfer of sialic acid to the galactose residue in lactosylceramide by CMP-sialic acid:lactosylceramide sialyltransferase (CMP-NeuAc: Gal ⁇ 1-4Glc ⁇ 1-1'Cer ⁇ 2,3-sialyltransferase; SAT-1).
  • CMP-NeuAc Gal ⁇ 1-4Glc ⁇ 1-1'Cer ⁇ 2,3-sialyltransferase
  • Enzymes which transfer sialic acid through an ⁇ 2-3 ketoside bond are described in, for example, Wienstein et al., J. Biol. Chem., 257, 13835 (1982); Gillespie et al., Glycoconj., 7, 469 (1990); Gillespie, W., Kelm, S. and Paulson, JC., J. Biol. Chem., 267, p21001-21010 (1992); Lee, YC., Kojima, N., Wada, E., Kurosawa, N., Nakaoka, T., Hashimoto, T. and Tsuji, S., J. Biol. Chem., 269, p10028-10033 (1994); Kim.
  • the present inventors have been successful in isolating cDNA having a nucleotide sequence encoding the sialyltransferase which participates in the above-mentioned G M3 synthesis, by using an expression cloning method and based on the nucleotide sequence, they have clarified the structure of the above-mentioned sialyltransferase.
  • the enzyme is low in homology with the known sialyltransferase and is believed to be a new enzyme, differing from the ⁇ 2-8 sialyltransferase, with which the identity was presumed by Sandhoff, K. supra.
  • the present invention provides a sialyltransferase having the following properties and a DNA having a nucleotide sequence encoding it.
  • the present invention provides a sialyltransferase having the above-mentioned activity and having an amino acid sequence shown by SEQ ID No: 5 on the C-terminal of the amino acid sequence thereof and a DNA encoding it as well as a sialyltransferase having the above-mentioned activity and having an amino acid sequence shown by SEQ ID NO: 6 and a DNA encoding it.
  • the sialic acid donor is preferably cytidine 5-monophosphsate-sialic acid (CMP-sialic acid).
  • the above mentioned enzymes and DNAs are preferably those derived from a mammal, most preferably those derived from human.
  • the present invention also provides a sialyltransferase comprising the polypeptide (a) or the polypeptide (b) below and a DNA encoding it.
  • DNA of the present invention examples include a DNA having a nucleotide sequence encoding all the amino acid sequence shown by SEQ ID NO: 2 or a DNA having partial sequences thereof, for example, DNA having a nucleotide sequence shown by SEQ ID NO: 1.
  • the present invention provides a polypeptide comprising all or part of the polypeptide of sialyltransferase encoded by the nucleotide sequence of the above-mentioned DNA. From the polypeptide, a transmembrane domain may be deleted.
  • sialyltransferase of the present invention which has an enzyme activity of transferring sialic acid from a sialic acid donor selectively to the 3-hydroxyl group of the galactose residue contained in lactosylceramide as a sialic acid acceptor to produce ganglioside G M3 is also described as "sialyltransferase-1" or "SAT-1" for convenience's sake.
  • a DNA of ⁇ 2-3 sialyltransferase (SAT-1) which synthesize from lactosylceramide, ganglioside G M3 that induces cell differentiation.
  • ⁇ 2-3 sialyltransferase i.e., G M3 synthase
  • G M3 synthase can be obtained easily by the use of the above-mentioned DNA.
  • Fig. 1 is a schematic view showing the structure of ⁇ 2-3 sialyltransferase (SAT-1) of the present invention, in which ⁇ indicates an N-glycosylation site presumed from the amino acid sequence and TM indicates a transmembrane domain presumed from the amino acid sequence.
  • SAT-1 sialyltransferase
  • Fig. 2 is a diagram comparing the amino acid sequence of a sialyl motif (L and S) region of SAT-1 with a sialyl motif region of another sialyltransferase; the marks "*" under the sequences indicate common sequences appearing in the sialyl motif of other sialyltransferases, the marks "*" above the sequences indicate the part of SAT-1 that contains the amino acids identical with the amino acids in the common sequences of the sialyl motif, and the marks "-" above the sequences indicate the part that contains amino acids different from those in the common sequences of the sialyl motif.
  • Fig. 3 is a graph illustrating hydropathy-plot of an amino acid sequence of SAT-1 deduced from a nucleotide sequence of the DNA of the present invention.
  • DNA encoding sialyltransferase-1 of the present invention (DNA of the present invention)
  • the DNA of the present invention includes DNAs having nucleotide sequences encoding sialyltransferases containing various polypeptides, the sialyltransferases having the following physico-chemical properties:
  • the sialyltransferase selectively transfers sialic acid from a sialic acid donor to a 3-hydroxyl group of a galactose residue contained in lactosylceramide as a sialic acid acceptor, to produce ganglioside G M3 .
  • the enzyme does not transfer substantially sialic acid to a position except for a 3-hydroxyl group of a galactose residue of the above-mentioned sialic acid acceptor.
  • the sialic acid acceptor is preferably CMP-sialic acid.
  • This enzyme has high sialic acid transferring activity within the range of an enzyme reaction mixture pH of from 6.0 to 7.0 as measured by the enzyme activity assay method described in the examples below.
  • the activity of sialyltransferase increases at least 1.5 times in the presence of 10 mM of Mn 2- as compared with the case in the absence thereof.
  • the DNA of the present invention includes DNAs which have nucleotide sequences encoding various polypeptides of sialyltransferases containing polypeptides which have the activity (1) above and having an amino acid sequence shown by SEQ ID NO: 5 on the C-terminal of the amino acid sequence thereof as well as those DNAs which have nucleotide sequences encoding various polypeprides of sialyltransferases containing polypeptides which have the activity (1) above and having an amino acid sequence shown by SEQ ID NO: 6.
  • the amino acid sequence shown by SEQ ID NO: 6 is a sequence which corresponds to a sialyl motif existing in the sialyltransferase and which usually exists in the part corresponding to the amino acid numbers 136-183 in the amino acid sequence shown by SEQ ID NO: 2 in the amino acid sequence of the polypeptide of the sialyltransferase.
  • the DNA of the present invention also includes those encoding the polypeptides (a) or (b) below and their nucleotide sequence is not limited particularly as far as they encode those polypeptides.
  • the amino acid sequence shown by SEQ ID NO: 2 may have therein substitution, deletion, insertion or rearrangement of one or a few amino acid residues that do not substantially impair the activity of transferring sialic acid from a sialic acid donor selectively to a 3-hydroxyl group of a galactose residue contained in lactosylceramide as a sialic acid acceptor to produce ganglioside G M3 .
  • the DNA of the present invention includes DNAs having any of substitution, deletion, insertion and rearrangement in their nucleotide sequence, encoding such polypeptides having therein any of substitution, deletion, insertion and rearrangement in their amino acid sequence.
  • a few amino acid residues refers to the number of amino acids that may cause variations to the extent that the activity of the enzyme is not lost. In the case of a polypeptide consisting of 360 amino acid residues, for example, it means about 20 or less.
  • the activity of the enzyme can be measured without difficulty by a known method (JP-A 7-327678), by changing cDNA to be introduced into host cells and a substrate for the enzyme and since one skilled in the art can practice with ease, for example, by the method specifically described herein, the substitution, deletion, insertion or rearrangement of one or a few amino acid residues that does not substantially impart the target activity can be readily selected by using the presence or absence of the enzyme activity as an indicator.
  • substitution, deletion, insertion or rearrangement in the nucleotide sequence can be introduced into a DNA by synthesizing a sequence having a restriction enzyme-cleaved end on each terminal and containing bolt sides of the mutation point, i.e., substitution, deletion, insertion or rearrangement, followed by replacing this for the corresponding part of the nucleotide sequence of a non-mutated DNA.
  • site-specific mutagenesis (Kramer, W. and Frits, H. J., Meth. in Enzymol., 154, 350 (1987); Kunkel, T. A. et al., Meth.
  • DNA encoding a polypeptide having substitution, deletion, insertion or rearrangement of one or a few amino acid residues that does not substantially impair the activity in the amino acid sequence shown by SEQ ID NO: 2, may be obtained as a homologous or alleic variant.
  • the DNA of the present invention includes DNAs having nucleotide sequences encoding all the amino acid sequence shown by SEQ ID NO: 2 or DNAs having partial nucleotide sequences thereof. These DNAs are preferred but the present invention is not limited thereto.
  • the term "DNAs having partial nucleotide sequences" as used herein refers to, for example, those DNAs which hybridize with DNA encoding a polypeptide of sialyltransferase-1 so that they can be used as a probe for detecting the DNA of sialyltransferase-1; which encode the polypeptides having sialyltransferase-1 activity; or which encode the polypeptides having antigenicity similar to that of sialyltransferase-1.
  • the hybridization referred to above may be performed under stringent conditions by a method which is conventionally used for hybridizing DNA or RNA with DNA, such as screening.
  • the conditions used in screening DNA or the like include prehybridizing a target DNA in a solution containing 50% formamide, 5 ⁇ SSPE (sodium chloride/sodium phosphate/EDTA buffer), 5 ⁇ Denhardt's solution, 0.5% SDS, and 50 ⁇ g/ml of denatured salmon sperm DNA, adding to the solution 32 P-labeled DNA of the present invention (for example, DNA having a nucleotide sequence shown by SEQ ID NO: 1), hybridizing it at 42°C for 16 hours, and then washing it sequentially with 1 ⁇ SSPE, 1% SDS, 0.1 ⁇ SSPE, and 0.1% SDS at 55°C.
  • the DNA of the present invention includes DNAs having the whole nucleotide sequence shown by SEQ ID NO: 1 or partial sequences thereof, which are preferred. Specific examples of these DNAs include a DNA having a nucleotide sequence of base numbers 202-1278 in the sequence shown by SEQ ID NO: 1.
  • the 5'-terminal portion of the open reading frame of cDNA of sialyltransferase-1 contains three in-frame ATG codons.
  • the nucleotide sequences around the three ATG codons conserve each a purine base at the -3 position. This satisfies the Kozak's finding on efficient translation (Kozak, M., (1986) Cell, 44, 283-292) so that it is possible that any of the ATG codons functions as an initiation codon.
  • ⁇ -1,4-galactosyltransferase is known to contain two in-frame ATG codons (Nakazawa, K. et al. (1988) J. Biochem., 104, 165-168; Shaper, N. et al. (1988) J. Biol. Chem., 263, 10420-10428).
  • Shaper et al. showed that in the case of ⁇ -1,4-galactosyltransferase, translation starts at two sites, resulting in that the enzyme is synthesized in both longer and shorter forms.
  • Lopez et al. presented the evidence suggesting that the longer form preferentially targets membrane while the shorter form exists mainly in Golgi apparatus (Lopez, L.
  • Fig. 1 is a graph illustrating hydropathy plot prepared from this amino acid sequence. From Fig. 1 it can be seen that there exists in the sequence a 14 residue-long continuous, remarkably hydrophobic part ranging from the 16th to 29th amino acid residues counting from the N-terminal, which suggests that the protein has a transmembrane domain.
  • DNA of the present invention also includes DNAs having different nucleotide sequences by degeneracy of genetic codes.
  • the DNA of the present invention include DNAs or RNAs complementary to the DNA of the present invention.
  • the DNA of the present invention may be of a single strand of only a coding strand which encodes SAT-1 or a double strand of the single strand and a DNA or RNA strand having a nucleotide sequence complementary thereto.
  • the DNA of the present invention may have a nucleotide sequence over the whole encoding region which encodes the whole peptide of SAT-1 or a nucleotide sequence encoding only a part of the polypeptide of SAT-1.
  • mammal sialyltransferases are known to have high homology in their amino acid sequence.
  • the polypeptide which the DNA of the present invention encodes is expected to have a homology of about 65% or more in the species. Therefore, polypeptides having high homology with the polypeptides encoded by the DNAs of the present invention specifically disclosed herein and DNAs encoding such polypeptides (such as homologous or alleic variants) are also embraced by the present invention.
  • the polypeptide of SAT-1 has a transmembrane domain.
  • polypeptide of SAT-1 includes, for example, an amino acid sequence of amino acids numbers 38 to 359 in the amino acid sequence shown by SEQ ID NO: 2.
  • the DNA of the present invention As the amino acid sequence of the polypeptide of SAT-1 has been clarified by the present invention, it is possible to obtain the DNA by amplification from chromosomal DNA or m-RNA by a PCR method (polymerase chain reaction method) using an oligonucleotide primer prepared based on the amino acid sequence.
  • the DNA of the present invention can also be produced by an expression cloning method, particularly the method which comprises the following steps.
  • the whole length of cDNA of the above-mentioned SAT-1 is normally selected by means of screening.
  • Cancer cells are preferably anchorage independent cells.
  • Such cancer cells include blood cell lymphoma and leukemia cells, which are preferred.
  • Such cells are preferred mammalian-derived cells, for example, human-derived HL-60 (ATCC CCL240), MOLT-4 (ATCC CRL 1582), and U937 (ATCC CRL1593) and mouse-derived M1 (ATCC TIBl92) and fresh myelogenous leukemia cells can also be used.
  • human-derived cells and HL-60 cells are particular preferred since differentiation induction is readily performed. Differentiation is induced by cultivating the cultivated cancer cell line for 20 hours or more, preferably for about 24 to 48 hours, after adding a differentiation inducing agent to the cancer cell line.
  • Cultivation may be performed under conditions that are suited for the cells used. Usually, as general cell culture conditions, there can be used conditions of 5-7 vol% of CO 2 and 95-93 vol% of air at 37-38°C.
  • the differentiation inducing agent there can be used, for example, phorbol ester (12-O-tetradecanoyl phorbol ester (TPA) etc.), dimethyl sulfoxide (DMSO), retinoic acid (RA), and 1 ⁇ ,25-dihydroxyvitamin D 3 (1 ⁇ ,25(OH 2 D 3 )) and the like.
  • TPA phorbol ester
  • DMSO dimethyl sulfoxide
  • RA retinoic acid
  • 1 ⁇ ,25-dihydroxyvitamin D 3 1 ⁇ ,25(OH 2 D 3 )
  • the present invention is not limited to the use of a particular one, preferred among them is TPA since it has relatively uniform differentiation inducing activity toward many leukemia cell lines.
  • TPA is used as a differentiation inducing agent
  • 48 hour cultivation in the presence of TPA in an amount of about 24 nM leads to the differentiation of HL-60 into monocyte/macrophage like cells, showing morphological changes.
  • RNA is prepared from the cells by a known method, for example, a guanidine thiocyanate/CsC1 method (Kingston, R. E., (1991) in Current Protocols in Molecular Biology, Suppl. 14, Unit 4.2, Green Publishing Associates and Wiley Interscience, New York). From the total RNA thus obtained is purified poly(A) + RNA by oligo-(dT)cellulose column chromatography or the like.
  • PCR may be performed In the same manner as a conventional method. Specific method thereof may be as follows.
  • a buffer solution (final volume 20 ⁇ l) containing 1 ⁇ l of poly(A) + RNA, 100 pmol of oligo-(dT), 100 pmol each of random oligonucleotide primers, 500 ⁇ l each of 4 kinds of deoxyribonucleoside triphosphates, 200 units of M-MLV reverse transcriptase (Gibco BRL), 1 mM dithiothreitol (DTT), 120 units of RNase (ribonuclease) inhibitor (manufactured by TAKARA SHUZO Co., LTD.) was incubated at 50°C for 60 minutes to synthesize a cDNA primary strand.
  • reaction mixture final volume 50 ⁇ l containing 5 ⁇ l of the above-mentioned reverse transcriptase reaction mixture, 100 pmol each of random oligonucleotide primers, 250 ⁇ M each of 4 kinds of deoxyribonucleoside triphosphates, and 1.25 units of Taq polymerase was incubated by repeating 35 cycles of 95°C for 1 minute, 46 to 62°C for 1 minute, and 72°C for 2 minutes.
  • the cDNA of cancer cells thus obtained is made to be held by an expression vector and introduced into host cells for screening the host cells.
  • the host cells there can be used any cells as far as they are cells of a mammalian-derived cell line which are lactosylceramide-positive. Examples of such include human Namalwa cells (Hosoi et al.: Cytotechnology, 1, 151 (1988)), Chinese hamster-derived CHO cells (ATCC CCL61, etc.), monkey-derived COS cells (ATCC CRL1650, etc.), mouse-derived 3LL cells (Taniguchi, S., Shinshu University Aging Adaptation Research Center)) and so on.
  • those cultivated cells which are further G M3 -negative are preferred.
  • examples of such cells include 3LL-HK46 cell (Inokuchi, J., (Seikagaku Corporation)), a mutant of 3LL cell, which is preferred.
  • the expression vector includes pCEV18 (Maruyama, K. (donated from Tokyo University, Medical Science Research Institute, now Tokyo Medical Dental University), pCXN2 (Niwa, H., Yamamura, K. and Miyazaki, J.
  • pCEV18 be used as an expression vector.
  • Introduction, into a vector, of the PCR product prepared based on poly(A) + RNA of a cancer cell as described above is performed by a method selected from known methods which is suited for the vector to be used.
  • the cDNA library constructed by the above-mentioned method is transfected to host cells by a known technique. Specifically, there can be cited, for example, an electroporation method (Miyaji, et al., Cytotechnology, 3, 133 (1990)), a calcium phosphate method (JP-A 2-227075), and a lipofection method (Philip, L. F. et al., Proc. Natl. Acad. Sci. USA, 84, 7413 (1987)), and selected suitably.
  • the electroporation method is preferred.
  • cDNA encoding SAT-1 When cDNA encoding SAT-1 is detected, it is also possible to transfect, in advance or simultaneously, to host cells, DNA encoding human ⁇ 2-8 sialyltransferase (JP-A 7-327678, etc.), an enzyme which synthesizes G D3 that is known to be synthesized from G M3 , express on cell membrane, and can be detected with ease, directly from G M3 . Such a pretransfection or simultaneous transfection is preferred.
  • pCEV18 holding the cDNA library may be transfected to normal 3LL-HK46 cells directly or to 3LL-ST28, a recombinant made by introducing in advance the cDNA of ⁇ 2-8 sialyltransferase into 3LL-HK46 cells using an eukaryote expression vector such as pCEV18.
  • pCEV18 containing the cDNA library may be transfected to 3LL-HK46 cells simultaneously with the vector into which the cDNA of ⁇ 2-8 sialyltransferase has been introduced.
  • Host cells into which cDNA library has been introduced are cultivated under generally used cell culture conditions. After at least 24 hours, preferably after 36 to 48 hours, from the introduction of cDNA, the host cells are stained by immuno-staining using an anti-ganglioside antibody or a lectin which bonds to ganglioside.
  • the staining method using antibodies is more accurate and preferred.
  • the expressing cells are detected by using an antibody which recognizes G M3 that has been expressed on the cell membrane, for example, anti-G M3 monoclonal antibody M2590 (the monoclonal antibody which L612 (ATCC CRL10724)) produces: J. Biol.
  • the immuno-staining can be performed by a conventional method.
  • G D3 which is synthesized from the G M3 produced upon the introduction of the DNA of the present invention is detected.
  • Immuno-staining for detecting G D3 may be performed by a conventional method generally used (JP-A 2-327678).
  • the primary antibody to be used is not limited particularly as far as it is an antibody which recognizes G D3 .
  • monoclonal antibodies are preferred and examples of which include anti-G D3 monoclonal antibody R24 (monoclonal antibody which a hybridoma (ATCC HB8445) produces: Cancer Res., 49, p191-196 (1989)), which is preferred.
  • the immuno-staining method using the above-mentioned generally employed antibodies is performed as follows. Namely, the host cells (1 ⁇ 10 5 cells) after the above-mentioned cultivation are washed about 2 or 3 times by centrifugation in a BSA solution (0.1% BSA PBS(+)) and the cells are suspended in 100 ⁇ l of the BSA solution containing the primary antibody.
  • the cells After allowing the suspension to react under ice cooling for 30 minutes, the cells are washed with the above-mentioned BSA solution 2 times or so. Further, in 100 ⁇ l of a BSA solution containing 1 ⁇ l of FITC-labeled secondary antibody against the primary antibody, the cells are left to stand for 30 minutes under ice cooling for reaction. The cells are washed with a BSA solution once and those cells which show strong fluorescence are detected by using a flow cytometer (FACScalibur: manufactured by Becton Dickinson). Cells showing strong fluorescence, for example, 5% of the total cells, are selected by a cell sorter and plasmid DNA is extracted therefrom. The extraction of plasmid DNA from the host cells is performed by a conventional method.
  • the plasmid DNA obtained by the above-described operation is transfected to a suitable host cell line and the procedure of immuno-staining with the anti-G M3 antibody and recovery of strong fluorescence-showing cells in an amount of 5% of the total cells by using a flow cytometer, for example, is repeated twice or more to enrich the target cDNA by sorting.
  • the host cell used for the sorting is preferably cultivated mammalian cells, of which 3LL-HK46 is particularly preferred.
  • the vector to be used is not limited particularly and any expression vectors for mammalian cells may be used, but pCEV18 is preferred.
  • the above-mentioned vector holding the target cDNA enriched by sorting is transfected to mammalian-derived cultivated cells lacking G D3 synthesis pathway, such as 3KK-HK46, simultaneously with the expression vector made by introducing the above-mentioned human ⁇ 2-8 sialyltransferase cDNA by a known method into an expression vector for mammalian cells, such as pBKCMV (manufactured by STRATAGENE CO.) and detection by immuno-staining and a flow cytometer is conducted in the same manner as described above to obtain cells that show strong fluorescence in an amount of 5% of the total cells. From these cells is extracted plasmid DNA by a conventional method.
  • the cDNA excised by a conventional method from the plasmid DNA is used to transform E. coli DH10B (manufactured by GIBCO CO.) therewith, and the transfected E. coli cells are inoculated so that 100 colonies per well can be formed, followed by sib selection to finally obtain a clone, pCEV4C7, containing an insert (4C7) of about 2.1 kbp.
  • nucleotide sequence of the cDNA obtained as described above, as is or after subcloning in a suitable plasmid such as pCRII, is determined by a conventional method.
  • nucleotide sequence of the SAT-1-encoding cDNA determined as described above and amino acid sequence deduced from the nucleotide sequence are shown by SEQ ID NO: 1 and the amino acid sequence alone is shown by SEQ ID NO: 2.
  • the DNA encoding the polypeptide of SAT-1 which lacks a transmembrane domain i.e., which is in the form of solubilized protein can be obtained as follows. Namely, based on the nucleotide sequence shown by SEQ ID NO: 1 is prepared a primer selected to have a truncated form at the N-terminal side of the polypeptide of the enzyme, and the target DNA is amplified by a PCR method using the cDNA of cloned SAT-1 as a template.
  • an oligonucleotide primer is synthesized based on the nucleotide sequence existing at the 3'- and 5'-terminals of the target nucleotide sequence, for example.
  • An oligonucleotide primers having nucleotide sequences are shown by SEQ ID NO: 3 and SEQ ID NO: 4, respectively, for example, may be used as 5'- and 3'- primers, respectively, in order to perform PCR. Then, the target DNA can be obtained from the amplified PCR product, after purification, if desired.
  • the present invention provides polypeptides which comprise the whole or part or the above-mentioned SAT-1 polypeptide encoded by the DNA of the present invention.
  • the "part" of the polypeptide as used herein means a part which has a kind of activity or function such as having sialyltransferase-1 activity or having antigenicity.
  • the polypeptide may be single or fused with one or more other polypeptides.
  • the polypeptide may also lack a transmembrane domain.
  • the polypeptide may be with or without a sugar chain.
  • the kind of sugar chain is not limited particularly.
  • Such a polypeptide can be obtained by, for example, the production method as described below. Determination of presence or absence of the above-mentioned activity or function can be practiced by changing the cDNA to be introduced into host cells and the substrate for tne enzyme in the assay of enzyme activity as described in JP-A 7-327678 and can be performed with ease by one skilled in the art based on, for example, the method described herein specifically.
  • the SAT-1 polypeptide can be produced by cultivating cells transformed with the above-mentioned DNA of the present invention in a suitable medium, allowing the cells to produce and accumulate in the culture the polypeptide encoded by the DNA of the present invention, and collecting the SAT-1 polypeptide from the culture.
  • the cells transformed with the DNA of the present invention can be obtained by inserting a fragment of the DNA of the present invention into a known expression vector to construct a recombinant plasmid and conducting transformation with the recombinant plasmid.
  • the cells which can be used include prokaryotic cells such as E. coli and eukaryotic cells such as mammalian cells.
  • prokaryotic cells such as E. coli
  • eukaryotic cells such as mammalian cells.
  • a host-vector-system usually used in the production of proteins may be used. While it is preferred to use a combination of mammalian-derived cultivated cell, such as 3LL-HK46 cell, 3LL-ST28 cell or COS-1 cell, and an expression vector for mammalian cells, such as pCEV18, pME18S (Maruyama et al., Med. Immunol., 20, 27 (1990)), the present invention is not limited thereto.
  • the medium and cultivation conditions may be selected suitably depending on the host cell to be used.
  • DNA of the present invention may be expressed over the whole length thereof, it may be suppressed as a fused polypeptide with another polypeptide. Also, a part of the DNA of the present invention may be expressed as a partial polypeptide.
  • a specific example of construction of recombinant plasmid which expresses the above-mentioned fused polypeptide is by the following method. Namely, the DNA of the present invention is incorporated into a vector constructed so that a gene introduced into a plasmid such as pGIR201protA (Kitagawa, H. and Paulson, J. C., J. Biol. Chem., 269, 1394-1401 (1994)) can be expressed as a fused protein by a conventional method to construct a vector having genes for plural proteins on the same reading frame. Then, from the vector is excised NheI fragment, which encodes a fused protein, and the fragment is ligated to a suitable vector such as pCEV18 by the same operation as described above.
  • a suitable vector such as pCEV18
  • the polypeptide of the present invention can be collected from the culture by a known purification method for polypeptides. Specifically, there can be used affinity chromatography using a Sepharose column to which lactosylceramide or CMP-sialic acid, for example is bonded.
  • affinity chromatography using a Sepharose column to which lactosylceramide or CMP-sialic acid, for example is bonded.
  • the culture of the host cell can be purified by affinity chromatography using a column to which a substance is bonded having high affinity for the polypeptide fused with SAT-1, such as antibody, in addition to the above-mentioned affinity column.
  • a linker having an amino acid sequence which a specified proteolytic enzyme can recognize and cleave may be incorporated in advance between the SAT-1 and the polypeptide of other protein in the fused polypeptide. This allows the cleavage to occur at the linker site of the fused polypeptide after purification thereof so that SAT-1, whose purification has been difficult heretofore can be obtained.
  • the combination of the specified proteolytic enzyme and the specified sequence which the enzyme recognizes is, for example, a combination of signal peptidase which acts upon the synthesis of proinsulin and signal peptide of insulin.
  • the above-mentioned culture includes a medium and cells in the medium.
  • the activity of sialyltransferase can be assayed by changing the substrate for the enzyme in a conventional assay method for assaying general ganglioside synthesis (JP-A 7-327678).
  • a suitable amount of the culture or the enzyme purified by the above-described method is added to a reaction mixture containing 100 mM sodium cacodylate, 10 mM manganese chloride, 0.2 mM CMP-radioactive substance-labeled sialic acid, 0.4 mM lactosylceramide, and 0.3% Triton CF-54.
  • the mixture is adjusted to pH 6.5 and incubated at 37°C for 2 hours and the reaction product is developed by a conventional thin layer chromatography and the enzyme activity is determined by using Fujix BAS2000 Bio Imaging Analyzer (manufactured by Fuji Photo Film Co., Ltd.).
  • HL-60 cells were cultivated in RPMI-1640 (manufactured by NISSUI PHARM. CO.) containing 24 nM TPA under the conditions of 5 vol% CO 2 and 95 vol% air at 37°C for 48 hours to induce differentiation.
  • the cultivated cells were collected by centrifugation at 1000 ⁇ g and total RNA was prepared from the collected cells by guanidine thiocyanate-acid-phenol-chloroform method (AGPC method). From differentiated 5 ⁇ 10 6 cells was obtained about 40 ⁇ g of RNA. From the RNA, poly(A) + RNA was purified by oligo-(dT) cellulose column chromatography.
  • the poly(A) + RNA was used as a template for reverse transcription reaction to construct a primary strand of DNA, and the DNA in turn was used for synthesizing double-stranded cDNA (Gubber, V. and Hoffman, B. J., Gene, 25, 283 (1983)).
  • a restriction enzyme BSTX1 adapter To the double-stranded cDNA was ligated a restriction enzyme BSTX1 adapter and the ligate was introduced into the BSTX1 site of pCEV18 to construct a cDNA library.
  • the above-mentioned cDNA library was introduced into 3LL-HK46 cells by using an electroporation method and the transfected cells were cultivated for 48 hours under the conditions of 5 vol% CO 2 and 95 vol% air at 37°C.
  • the 3LL-HK46 cells after the cultivation were immuno-stained with M2590, anti-G M3 antibody, and with FITC-labeled rabbit anti-murine IgG antibody.
  • the stained cells were passed through a flow cytometer (FACScalibur) to detect fluorescence-positive cells. 5% of the cells on the positive side were collected and plasmid DNA was prepared therefrom. Then, the procedures of introduction of cDNA into 3LL-HK46 cells by electroporation, 48-hour cultivation of the transfected cells, immuno-staining, and detection and collection by using a flow cytometer were further repeated twice.
  • the plasmids finally obtained by this method were introduced into 3LL-HK46 cells together with pBKCMV G D3 (a plasmid obtained by introducing the cDNA of human ⁇ 2-8 sialyltransferase (G D3 synthase) to pBKCMV plasmid vector manufactured by STRATAGENE CO.). After cultivating them for 48 hours, the resulting cells were immuno-stained with R24, anti-G D3 antibody, and with FITC-labeled rabbit anti-murine IgG antibody, and 5% of the total cells which show strong fluorescence were detected by a flow cytometer and collected.
  • G D3 a plasmid obtained by introducing the cDNA of human ⁇ 2-8 sialyltransferase (G D3 synthase) to pBKCMV plasmid vector manufactured by STRATAGENE CO.
  • the pCEV4C7 thus obtained was expressed in 3LL-HK46 cells temporarily and flow cytometry analysis was performed using anti-G M3 antibody (M2590) in the same manner as described above.
  • 3LL-HK46 cells temporarily expressing pCEV18, as a control, did not express G M3 on the cell membrane whereas 3LL-HK46 cells temporarily expressing pCEV4C7 expressed G M3 on the cell membrane and fluorescence was detected.
  • the nucleotide sequence of double-stranded DNA of pCEV4C7 was determined by a dideoxy chain termination method using an autocycle sequencing kit (manufactured by PHARMACIA CO.) and Pharmacia A.L.F. DNA sequencer (manufactured by PHARMACIA CO.).
  • the nucleotide sequence thus determined and an amino acid sequence deduced therefrom are shown by SEQ ID NO: 1 and the amino acid sequence alone is shown by SEQ ID NO: 2.
  • the cDNA insert 4C7 which is contained in pCEV4C7 is of about 2.1 kbp and is revealed to encode a protein (molecular weight 41,244 Da containing 359 amino acid residues starting with a nucleotide at 202 position as a translation initiation point.
  • Fig. 1 is a schematic view which illustrates the structure expected from the amino acid sequence. As a result of hydropathy plot analysis, the amino acid sequence was revealed to correspond to a type-2 membrane protein in which the transmembrane domain (TM in Fig. 1) exists in the region of the 16th to 29th amino acid residues on the N-terminals. Search of this sequence with gene data base in GenBank showed no high homology with any of the data therein.
  • sialyl motifs L and S in the sialyltransferase homologous region existing in the central part and C-terminal region of the sequence for sialyltransferase, relatively high homology was recognized although some substitution was observed (Fig. 2).
  • the sialyltransferases used for comparison were eleven (11) species, i.e., h2,3ST (JP-A 5-336963), rSTX (J. Biol. Chem., 268, 11504-11507 (1993)), rST3N-1 (J. Biol. Chem., 267, 21011-21019 (1992)), hST3N-2 (J. Biol.
  • SAT-1 which is encoded by the insert 4C7 in pCEV4C7 belongs to the sialyltransferase family.
  • amino acid sequence indicates existence of four consensus sequences of the N-glycosylation site ( ⁇ in Fig. 1), whereas the two sites thereof on the N-terminal side exist near the transmembrane domain and in the sialyl motifs so that these two N-terminal side sites could be less N-glycosylated as compared with the two sites on the C-terminal side.
  • pEV4C7 obtained by incorporating the above-mentioned SAT-1-encoding cDNA (4C7) into expression vector pCEV18 was transfected to 3LL-HK46 cells by an electroporation method and the G M3 synthase activity of the cells after 48-hour cultivation was assayed by the following method.
  • the G M3 synthase activity was high at pH 6.0 to 7.0, particularly at around pH 6.5 and increased at least 1.5 times in the presence of 10 mM of Mn 2+ .

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A sialyltransferase having the following physico-chemical properties:
  • (1) Activity:
       transfers sialic acid from a sialic acid donor selectively to a 3-hydroxyl group of a galactose residue contained in lactosylceramide as a sialic acid acceptor to produce ganglioside GM3;
  • (2) Optimal reaction pH:
       6.0 to 7.0; and
  • (3) Inhibition and activation:
       the activity increases at least 1.5 times with 10 mM of Mn2+ as compared with the case in the absence thereof.
    •

    Description

    BACKGROUND OF THE INVENTION
    The present invention relates to a sialyltransferase and to a DNA encoding the same. More particularly, the present invention relates to an enzyme which synthesizes ganglioside GM3 by transferring sialic acid to a galactose residue of lactosylceramide and to a DNA encoding the enzyme.
    Human myelogenous leukemia cell line HL-60, which is a cell line that has acquired the ability of infinite proliferation as a result of tumorigenic transformation, is used generally and widely as a model for leukemia cells (Collins, S.J. Gallo, R.C., and Gallagher, R.E., Nature (London), 270, 347-349 (1977); Collins, S.J., Blood, 70, 1223 (1987)). The cell line does not differentiate even after continued cultivation and continues to proliferate while it remains as undifferentiated cells. However, when cultivation is continued with addition of phorbol ester, which is widely used as a differentiation inducer, the cell line stops the proliferation of cells and takes an appearance similar to that of monocytes or macrophages. This indicates that differentiation has been induced. It has been reported that during this process, the amount of GM3, which is a kind of ganglioside, increases considerably (Nojiri, E., Takaku, F., Tetsuka, T., and Saito, M., Blood, 64, 534-541(1984)), and when the ganglioside GM3 is added exogenously, the cell line shows the same change as that observed with the addition of phorbol ester, i.e., the cells undergo monocytic differentiation (Saito, M., Terui, Y., and Nojiri, H., Biochem. Biophys. Res. Commun., 132, 223-231 (1985)). Also, in has been proved that in this differentiation process, GM3 itself has an activity of inducing differentiation (Nojiri, H., Takaku, F., Miura, Y., and Saito, M., Proc. Natl. Acad. Sci. U.S.A., 83, 782-786 (1986)), and that chemically synthesized GM3 also induces differentiation (Sugimoto, M. and Ogawa, T., Glycoconj. J., 2, 5-9 (1985); Saito, M., Nojiri, H., Ogino, H., Yuo, A., Ogura, H., Itoh, M., Tomita, K., Ogawa, T., Nagai, Y., and Kitagawa, S., FEBS Lett., 271, 85-88 (1990)).
    On the other hand, it has been elucidated that sialic acid-containing glycolipids, in particular ganglioside, bear important functions in various biological phenomena and not only its functions but also its biosynthesis are being clarified. In vertebrates, many gangliosides (ganglio-series gangliosides) have a common precursor, GM3, which has the simplest structure among major gangliosides and the GM3 synthesis affords a basis for the biosynthesis of gangliosides which have major functions.
    As described above, ganglioside GM3 itself participates in the proliferation/differentiation of cells and tissues and it is suggested that the ganglioside GM3 is a precursor for a group of higher gangliosides having various functions in vertebrates.
    GM3 has been considered to be synthesized from lactosylceramide by transfer of sialic acid to the galactose residue in lactosylceramide by CMP-sialic acid:lactosylceramide sialyltransferase (CMP-NeuAc: Galβ1-4Glcβ1-1'Cerα2,3-sialyltransferase; SAT-1). However, neither the transferase from human has been isolated nor the genes thereof have been identified.
    Enzymes which transfer sialic acid through an α2-3 ketoside bond are described in, for example, Wienstein et al., J. Biol. Chem., 257, 13835 (1982); Gillespie et al., Glycoconj., 7, 469 (1990); Gillespie, W., Kelm, S. and Paulson, JC., J. Biol. Chem., 267, p21001-21010 (1992); Lee, YC., Kojima, N., Wada, E., Kurosawa, N., Nakaoka, T., Hashimoto, T. and Tsuji, S., J. Biol. Chem., 269, p10028-10033 (1994); Kim. YJ., Kim, KS., Kim, SH., Kim, CH., Ko, JH., Choe, IS., Tsuji, S. and Lee, YC., Biochem. Biophys. Res. Commun., 228, p324-327 (1996); and JP-A 5-336963. However, none of the enzymes is known to be involved in the synthesis of GM3 or shows an enzyme activity of transferring sialic acid to lactosylceramide through an α2-3 ketoside bond. Sandhoff, K. et al. presume that α2-3 sialyltransferase (SAT4) is identical with the enzyme which synthesizes GM3 (J. Biol. Chem., 268, 5341 (1993)). However, this is a presumption based on an indirect method, which fails to support that the enzymes are identical to each other as a substance.
    In spite of various attempts which have been made in order to elucidate and control its biosynthesis according as the clarification of importance of ganglioside GM3 proceeds, the above-mentioned sialyltransferase, which relates closely to the synthesis of GM3, has not been isolated yet because of difficulty in preparing the enzyme protein and, hence, neither its gene expression control mechanism has been clarified yet nor its proteo-chemical or enzymological analysis has been performed successfully.
    SUMMARY OF THE INVENTION
    As a result of intensive investigation with view to elucidating the control mechanism of cell differentiation by carrying forward studies on gene expression control mechanism of and proteo-chemical and enzymological analyses of the above-mentioned sialyltransferase, the present inventors have been successful in isolating cDNA having a nucleotide sequence encoding the sialyltransferase which participates in the above-mentioned GM3 synthesis, by using an expression cloning method and based on the nucleotide sequence, they have clarified the structure of the above-mentioned sialyltransferase. As a result, it revealed that the enzyme is low in homology with the known sialyltransferase and is believed to be a new enzyme, differing from the α2-8 sialyltransferase, with which the identity was presumed by Sandhoff, K. supra.
    Accordingly, the present invention provides a sialyltransferase having the following properties and a DNA having a nucleotide sequence encoding it.
  • (1) Activity: The sialyltransferase transfers sialic acid from a sialic acid donor selectively to a 3-hydroxyl group of a galactose residue contained in lactosylceramide as a sialic acid acceptor to produce ganglioside GM3.
  • (2) Optimal reaction pH:
       6.0 to 7.0
  • (3) Activation: The activity increases at least 1.5 times with 10 mM of Mn2+ as compared with the case in the absence thereof.
    • Also, the present invention provides a sialyltransferase having the above-mentioned activity and having an amino acid sequence shown by SEQ ID No: 5 on the C-terminal of the amino acid sequence thereof and a DNA encoding it as well as a sialyltransferase having the above-mentioned activity and having an amino acid sequence shown by SEQ ID NO: 6 and a DNA encoding it.
    The sialic acid donor is preferably cytidine 5-monophosphsate-sialic acid (CMP-sialic acid).
    The above mentioned enzymes and DNAs are preferably those derived from a mammal, most preferably those derived from human.
    The present invention also provides a sialyltransferase comprising the polypeptide (a) or the polypeptide (b) below and a DNA encoding it.
  • (a) A polypeptide having an amino sequence shown by SEQ ID NO: 2.
  • (b) A polypeptide having an amino acid sequence (a) above, which has therein substitution, deletion, insertion or rearrangement of one or a few amino acid residues, said sialyltransferase having an enzyme activity of transferring sialic acid from a sialic acid donor selectively to the 5-hydroxyl group of galactose residue contained in lactosylceramide as a sialic acid acceptor to produce ganglioside GM3.
    • Specific examples of the DNA of the present invention include a DNA having a nucleotide sequence encoding all the amino acid sequence shown by SEQ ID NO: 2 or a DNA having partial sequences thereof, for example, DNA having a nucleotide sequence shown by SEQ ID NO: 1.
    Further, the present invention provides a polypeptide comprising all or part of the polypeptide of sialyltransferase encoded by the nucleotide sequence of the above-mentioned DNA. From the polypeptide, a transmembrane domain may be deleted.
    The phrase "encoding an enzyme" as used herein refers to encoding the polypeptide of the enzyme. Also, herein, the sialyltransferase of the present invention which has an enzyme activity of transferring sialic acid from a sialic acid donor selectively to the 3-hydroxyl group of the galactose residue contained in lactosylceramide as a sialic acid acceptor to produce ganglioside GM3 is also described as "sialyltransferase-1" or "SAT-1" for convenience's sake.
    According to the present invention, a DNA of α2-3 sialyltransferase (SAT-1) which synthesize from lactosylceramide, ganglioside GM3 that induces cell differentiation. According to the present invention, α2-3 sialyltransferase, i.e., GM3 synthase, can be obtained easily by the use of the above-mentioned DNA.
    Since the DNA encoding SAT-1 is provided by the present invention, the elucidation of expression mechanism thereof will give an expectation for elucidation of the mechanism of cell differentiation.
    BRIEF DESCRIPTION OF THE DRAWINGS
    Fig. 1 is a schematic view showing the structure of α2-3 sialyltransferase (SAT-1) of the present invention, in which Δ indicates an N-glycosylation site presumed from the amino acid sequence and TM indicates a transmembrane domain presumed from the amino acid sequence.
    Fig. 2 is a diagram comparing the amino acid sequence of a sialyl motif (L and S) region of SAT-1 with a sialyl motif region of another sialyltransferase; the marks "*" under the sequences indicate common sequences appearing in the sialyl motif of other sialyltransferases, the marks "*" above the sequences indicate the part of SAT-1 that contains the amino acids identical with the amino acids in the common sequences of the sialyl motif, and the marks "-" above the sequences indicate the part that contains amino acids different from those in the common sequences of the sialyl motif.
    Fig. 3 is a graph illustrating hydropathy-plot of an amino acid sequence of SAT-1 deduced from a nucleotide sequence of the DNA of the present invention.
    DETAILED DESCRIPTION OF THE INVENTION [1] DNA encoding sialyltransferase-1 of the present invention (DNA of the present invention)
    The DNA of the present invention includes DNAs having nucleotide sequences encoding sialyltransferases containing various polypeptides, the sialyltransferases having the following physico-chemical properties:
    (1) Activity:
    The sialyltransferase selectively transfers sialic acid from a sialic acid donor to a 3-hydroxyl group of a galactose residue contained in lactosylceramide as a sialic acid acceptor, to produce ganglioside GM3. In other words, the enzyme does not transfer substantially sialic acid to a position except for a 3-hydroxyl group of a galactose residue of the above-mentioned sialic acid acceptor. The sialic acid acceptor is preferably CMP-sialic acid.
    (2) Optimal reaction pH:
    This enzyme has high sialic acid transferring activity within the range of an enzyme reaction mixture pH of from 6.0 to 7.0 as measured by the enzyme activity assay method described in the examples below.
    (3) Activation:
    The activity of sialyltransferase increases at least 1.5 times in the presence of 10 mM of Mn2- as compared with the case in the absence thereof.
    Further, the DNA of the present invention includes DNAs which have nucleotide sequences encoding various polypeptides of sialyltransferases containing polypeptides which have the activity (1) above and having an amino acid sequence shown by SEQ ID NO: 5 on the C-terminal of the amino acid sequence thereof as well as those DNAs which have nucleotide sequences encoding various polypeprides of sialyltransferases containing polypeptides which have the activity (1) above and having an amino acid sequence shown by SEQ ID NO: 6. The amino acid sequence shown by SEQ ID NO: 6 is a sequence which corresponds to a sialyl motif existing in the sialyltransferase and which usually exists in the part corresponding to the amino acid numbers 136-183 in the amino acid sequence shown by SEQ ID NO: 2 in the amino acid sequence of the polypeptide of the sialyltransferase.
    The DNA of the present invention also includes those encoding the polypeptides (a) or (b) below and their nucleotide sequence is not limited particularly as far as they encode those polypeptides.
  • (a) A polypeptide having an amino sequence shown by SEQ ID NO: 2.
  • (b) A polypeptides having the amino acid sequence (a) above, which has therein substitution, deletion, insertion or rearrangement of one or a few amino acid residues and having an enzyme activity of transferring sialic acid from a sialic acid donor selectively to a 3-hydroxyl group or a galactose residue contained in lactosylceramide as a sialic acid acceptor to produce ganglioside GM3.
    • In other words, the amino acid sequence shown by SEQ ID NO: 2 may have therein substitution, deletion, insertion or rearrangement of one or a few amino acid residues that do not substantially impair the activity of transferring sialic acid from a sialic acid donor selectively to a 3-hydroxyl group of a galactose residue contained in lactosylceramide as a sialic acid acceptor to produce ganglioside GM3. The DNA of the present invention includes DNAs having any of substitution, deletion, insertion and rearrangement in their nucleotide sequence, encoding such polypeptides having therein any of substitution, deletion, insertion and rearrangement in their amino acid sequence. The term "a few amino acid residues" as used herein refers to the number of amino acids that may cause variations to the extent that the activity of the enzyme is not lost. In the case of a polypeptide consisting of 360 amino acid residues, for example, it means about 20 or less. The activity of the enzyme can be measured without difficulty by a known method (JP-A 7-327678), by changing cDNA to be introduced into host cells and a substrate for the enzyme and since one skilled in the art can practice with ease, for example, by the method specifically described herein, the substitution, deletion, insertion or rearrangement of one or a few amino acid residues that does not substantially impart the target activity can be readily selected by using the presence or absence of the enzyme activity as an indicator. The substitution, deletion, insertion or rearrangement in the nucleotide sequence can be introduced into a DNA by synthesizing a sequence having a restriction enzyme-cleaved end on each terminal and containing bolt sides of the mutation point, i.e., substitution, deletion, insertion or rearrangement, followed by replacing this for the corresponding part of the nucleotide sequence of a non-mutated DNA. Alternatively, site-specific mutagenesis (Kramer, W. and Frits, H. J., Meth. in Enzymol., 154, 350 (1987); Kunkel, T. A. et al., Meth. in Enzymol., 154, 367 (1987)) and the like can be used to introduce substitution, deletion, insertion or rearrangement into a DNA. Also, the DNA encoding a polypeptide having substitution, deletion, insertion or rearrangement of one or a few amino acid residues that does not substantially impair the activity in the amino acid sequence shown by SEQ ID NO: 2, may be obtained as a homologous or alleic variant.
    Specifically, the DNA of the present invention includes DNAs having nucleotide sequences encoding all the amino acid sequence shown by SEQ ID NO: 2 or DNAs having partial nucleotide sequences thereof. These DNAs are preferred but the present invention is not limited thereto. The term "DNAs having partial nucleotide sequences" as used herein refers to, for example, those DNAs which hybridize with DNA encoding a polypeptide of sialyltransferase-1 so that they can be used as a probe for detecting the DNA of sialyltransferase-1; which encode the polypeptides having sialyltransferase-1 activity; or which encode the polypeptides having antigenicity similar to that of sialyltransferase-1. The hybridization referred to above may be performed under stringent conditions by a method which is conventionally used for hybridizing DNA or RNA with DNA, such as screening. For example, the conditions used in screening DNA or the like include prehybridizing a target DNA in a solution containing 50% formamide, 5× SSPE (sodium chloride/sodium phosphate/EDTA buffer), 5× Denhardt's solution, 0.5% SDS, and 50 µg/ml of denatured salmon sperm DNA, adding to the solution 32P-labeled DNA of the present invention (for example, DNA having a nucleotide sequence shown by SEQ ID NO: 1), hybridizing it at 42°C for 16 hours, and then washing it sequentially with 1×SSPE, 1% SDS, 0.1×SSPE, and 0.1% SDS at 55°C. Although generally hybridization is performed mostly under the above-mentioned conditions, one skilled in the art can perform similar hybridization by changing the composition of each solution and conditions aiming at similar hybridization and, hence, the present invention is not limited to the above-described conditions as far as the conditions used enable one to obtain similar effects.
    More specifically, the DNA of the present invention includes DNAs having the whole nucleotide sequence shown by SEQ ID NO: 1 or partial sequences thereof, which are preferred. Specific examples of these DNAs include a DNA having a nucleotide sequence of base numbers 202-1278 in the sequence shown by SEQ ID NO: 1.
    In the nucleotide sequence shown by SEQ ID NO: 1, the 5'-terminal portion of the open reading frame of cDNA of sialyltransferase-1 contains three in-frame ATG codons. The nucleotide sequences around the three ATG codons conserve each a purine base at the -3 position. This satisfies the Kozak's finding on efficient translation (Kozak, M., (1986) Cell, 44, 283-292) so that it is possible that any of the ATG codons functions as an initiation codon.
    In the meantime, β-1,4-galactosyltransferase is known to contain two in-frame ATG codons (Nakazawa, K. et al. (1988) J. Biochem., 104, 165-168; Shaper, N. et al. (1988) J. Biol. Chem., 263, 10420-10428). Also, Shaper et al. showed that in the case of β-1,4-galactosyltransferase, translation starts at two sites, resulting in that the enzyme is synthesized in both longer and shorter forms. Further, Lopez et al. presented the evidence suggesting that the longer form preferentially targets membrane while the shorter form exists mainly in Golgi apparatus (Lopez, L. et al. (1991) J. Biol. Chem., 266, 15984-15591). Similarly, in the case of the sialyltransferase, there is the possibility that plural ATG codons serve as an initiation codon. This is not certain yet. However, no matter how ATG codon may be an initiation codon, it is common that the polypeptide of the above-mentioned sialyltransferase-1 is encoded. Therefore, DNAs having nucleotide sequences starting with the second and third ATG codons, respectively are also embraced by the present invention.
    From a single open reading frame starting with the first ATG codon in the sequence shown by SEQ ID NO: 1 is deduced a protein which consists of 359 amino acid residues, has a molecular weight of 41,244 Da, and contains four sites that can be an N-glycosylation site. Fig. 1 is a graph illustrating hydropathy plot prepared from this amino acid sequence. From Fig. 1 it can be seen that there exists in the sequence a 14 residue-long continuous, remarkably hydrophobic part ranging from the 16th to 29th amino acid residues counting from the N-terminal, which suggests that the protein has a transmembrane domain.
    It will be readily understood by one skilled in the art that the DNA of the present invention also includes DNAs having different nucleotide sequences by degeneracy of genetic codes.
    Further, the DNA of the present invention include DNAs or RNAs complementary to the DNA of the present invention. Furthermore, the DNA of the present invention may be of a single strand of only a coding strand which encodes SAT-1 or a double strand of the single strand and a DNA or RNA strand having a nucleotide sequence complementary thereto.
    Also, the DNA of the present invention may have a nucleotide sequence over the whole encoding region which encodes the whole peptide of SAT-1 or a nucleotide sequence encoding only a part of the polypeptide of SAT-1.
    Now, generally, mammal sialyltransferases are known to have high homology in their amino acid sequence. The polypeptide which the DNA of the present invention encodes is expected to have a homology of about 65% or more in the species. Therefore, polypeptides having high homology with the polypeptides encoded by the DNAs of the present invention specifically disclosed herein and DNAs encoding such polypeptides (such as homologous or alleic variants) are also embraced by the present invention. As described above, the polypeptide of SAT-1 has a transmembrane domain. The part of the polypeptide of SAT-1 that has lost the region starting from the N-terminal corresponding to the N-terminal inside the membrane and containing the region having the transmembrane domain is also embraced by the present invention. Such a polypeptide includes, for example, an amino acid sequence of amino acids numbers 38 to 359 in the amino acid sequence shown by SEQ ID NO: 2.
    [2] Method of producing the DNA of the invention
    Hereafter, a method of producing the DNA of the present invention will be explained in detail. As the amino acid sequence of the polypeptide of SAT-1 has been clarified by the present invention, it is possible to obtain the DNA by amplification from chromosomal DNA or m-RNA by a PCR method (polymerase chain reaction method) using an oligonucleotide primer prepared based on the amino acid sequence. Alternatively, the DNA of the present invention can also be produced by an expression cloning method, particularly the method which comprises the following steps.
  • (1) Cancer cells are treated with a differentiation inducing agent to cause differentiation.
  • (2) A cDNA library is prepared from differentiated cancer cells and is introduced into host cells.
  • (3) Host cells that have expressed ganglioside on the cell membrane are screened.
  • (4) The screened host cells are sorted to enrich the library.
  • (5) The introduced gene is excised from the enriched library.
    • The whole length of cDNA of the above-mentioned SAT-1 is normally selected by means of screening.
    Hereafter, an example of the method of producing the DNA of the present invention will be explained more specifically.
    (1) Differentiation induction in cancer cells
    Cancer cells are preferably anchorage independent cells. Such cancer cells include blood cell lymphoma and leukemia cells, which are preferred. As such cells are preferred mammalian-derived cells, for example, human-derived HL-60 (ATCC CCL240), MOLT-4 (ATCC CRL 1582), and U937 (ATCC CRL1593) and mouse-derived M1 (ATCC TIBl92) and fresh myelogenous leukemia cells can also be used. Among such cancer cells, most preferred are human-derived cells and HL-60 cells are particular preferred since differentiation induction is readily performed. Differentiation is induced by cultivating the cultivated cancer cell line for 20 hours or more, preferably for about 24 to 48 hours, after adding a differentiation inducing agent to the cancer cell line. Cultivation may be performed under conditions that are suited for the cells used. Usually, as general cell culture conditions, there can be used conditions of 5-7 vol% of CO2 and 95-93 vol% of air at 37-38°C. As the differentiation inducing agent, there can be used, for example, phorbol ester (12-O-tetradecanoyl phorbol ester (TPA) etc.), dimethyl sulfoxide (DMSO), retinoic acid (RA), and 1α,25-dihydroxyvitamin D3 (1α,25(OH2D3)) and the like. Although the present invention is not limited to the use of a particular one, preferred among them is TPA since it has relatively uniform differentiation inducing activity toward many leukemia cell lines. When HL-60 is used as a cancer cell and TPA is used as a differentiation inducing agent, 48 hour cultivation in the presence of TPA in an amount of about 24 nM leads to the differentiation of HL-60 into monocyte/macrophage like cells, showing morphological changes.
    (2) Construction of cDNA from differentiated cancer cells 1) Preparation of RNA from differentiated cancer cells
    The cancer cells of which dffferentiation is induced in above (1) are collected by centrifugation preferably at 500 to 2,000 × g and total RNA is prepared from the cells by a known method, for example, a guanidine thiocyanate/CsC1 method (Kingston, R. E., (1991) in Current Protocols in Molecular Biology, Suppl. 14, Unit 4.2, Green Publishing Associates and Wiley Interscience, New York). From the total RNA thus obtained is purified poly(A)+RNA by oligo-(dT)cellulose column chromatography or the like.
    2) Construction of cDNA from poly(A)+RNA
    Reverse transcription PCR using the above-mentioned poly(A)+RNA as a template and also an oligonucleotide primers allows amplification of cDNA derived from the cancer cells. PCR may be performed In the same manner as a conventional method. Specific method thereof may be as follows. Namely, a buffer solution (final volume 20 µl) containing 1 µl of poly(A)+RNA, 100 pmol of oligo-(dT), 100 pmol each of random oligonucleotide primers, 500 µl each of 4 kinds of deoxyribonucleoside triphosphates, 200 units of M-MLV reverse transcriptase (Gibco BRL), 1 mM dithiothreitol (DTT), 120 units of RNase (ribonuclease) inhibitor (manufactured by TAKARA SHUZO Co., LTD.) was incubated at 50°C for 60 minutes to synthesize a cDNA primary strand. Next, a reaction mixture (final volume 50 µl) containing 5 µl of the above-mentioned reverse transcriptase reaction mixture, 100 pmol each of random oligonucleotide primers, 250 µM each of 4 kinds of deoxyribonucleoside triphosphates, and 1.25 units of Taq polymerase was incubated by repeating 35 cycles of 95°C for 1 minute, 46 to 62°C for 1 minute, and 72°C for 2 minutes.
    The cDNA of cancer cells thus obtained is made to be held by an expression vector and introduced into host cells for screening the host cells. As the host cells, there can be used any cells as far as they are cells of a mammalian-derived cell line which are lactosylceramide-positive. Examples of such include human Namalwa cells (Hosoi et al.: Cytotechnology, 1, 151 (1988)), Chinese hamster-derived CHO cells (ATCC CCL61, etc.), monkey-derived COS cells (ATCC CRL1650, etc.), mouse-derived 3LL cells (Taniguchi, S., Shinshu University Aging Adaptation Research Center)) and so on. However, since the detection of SAT-1 enzyme activity can be made easier in the present invention, those cultivated cells which are further GM3-negative are preferred. Examples of such cells include 3LL-HK46 cell (Inokuchi, J., (Seikagaku Corporation)), a mutant of 3LL cell, which is preferred. The expression vector includes pCEV18 (Maruyama, K. (donated from Tokyo University, Medical Science Research Institute, now Tokyo Medical Dental University), pCXN2 (Niwa, H., Yamamura, K. and Miyazaki, J. (Gene, 108, p193-200 (1991)), pFLAG-CMV-2 (manufactured by Eastman Kodak), pAGE107 (Miyaji et al., Cytotechnology, 3, 133 (1990)), pAS3-3 (JP-A 2-227075), pAMoERC3Sc(JP-A 5-336963), pcD2 (Chen, C. et al., Mol. Cell. Biol., 7, 2745-2752 (1987)) and the like and can be selected appropriately taking into consideration the host cell to be used. For example, when 3LL-HK46 is used as a host cell, it is preferred that pCEV18 be used as an expression vector. Introduction, into a vector, of the PCR product prepared based on poly(A)+RNA of a cancer cell as described above is performed by a method selected from known methods which is suited for the vector to be used.
    3) Introduction of cDNA library into a host cell
    The cDNA library constructed by the above-mentioned method is transfected to host cells by a known technique. Specifically, there can be cited, for example, an electroporation method (Miyaji, et al., Cytotechnology, 3, 133 (1990)), a calcium phosphate method (JP-A 2-227075), and a lipofection method (Philip, L. F. et al., Proc. Natl. Acad. Sci. USA, 84, 7413 (1987)), and selected suitably. However, the electroporation method is preferred. When cDNA encoding SAT-1 is detected, it is also possible to transfect, in advance or simultaneously, to host cells, DNA encoding human α2-8 sialyltransferase (JP-A 7-327678, etc.), an enzyme which synthesizes GD3 that is known to be synthesized from GM3, express on cell membrane, and can be detected with ease, directly from GM3. Such a pretransfection or simultaneous transfection is preferred. Therefore, when the cDNA library constructed by using pCEV18, for example, as a vector is introduced into 3LL-HK46 cells having no GD3 synthesis pathway as a host cell, pCEV18 holding the cDNA library may be transfected to normal 3LL-HK46 cells directly or to 3LL-ST28, a recombinant made by introducing in advance the cDNA of α2-8 sialyltransferase into 3LL-HK46 cells using an eukaryote expression vector such as pCEV18. Also, pCEV18 containing the cDNA library may be transfected to 3LL-HK46 cells simultaneously with the vector into which the cDNA of α2-8 sialyltransferase has been introduced.
    (3) Detection of host cells expressing ganglioside
    Host cells into which cDNA library has been introduced are cultivated under generally used cell culture conditions. After at least 24 hours, preferably after 36 to 48 hours, from the introduction of cDNA, the host cells are stained by immuno-staining using an anti-ganglioside antibody or a lectin which bonds to ganglioside. The staining method using antibodies is more accurate and preferred. For example, when 3LL-HK46 cell is used as a host cell, the expressing cells are detected by using an antibody which recognizes GM3 that has been expressed on the cell membrane, for example, anti-GM3 monoclonal antibody M2590 (the monoclonal antibody which L612 (ATCC CRL10724)) produces: J. Biol. Chem., 260, 13328-13333 (1985)). The immuno-staining can be performed by a conventional method. When the above-mentioned 3LL-ST28 is used as a host cell, for example, GD3 which is synthesized from the GM3 produced upon the introduction of the DNA of the present invention is detected. Immuno-staining for detecting GD3 may be performed by a conventional method generally used (JP-A 2-327678). In this case, the primary antibody to be used is not limited particularly as far as it is an antibody which recognizes GD3. However, monoclonal antibodies are preferred and examples of which include anti-GD3 monoclonal antibody R24 (monoclonal antibody which a hybridoma (ATCC HB8445) produces: Cancer Res., 49, p191-196 (1989)), which is preferred. Specifically, the immuno-staining method using the above-mentioned generally employed antibodies is performed as follows. Namely, the host cells (1×105 cells) after the above-mentioned cultivation are washed about 2 or 3 times by centrifugation in a BSA solution (0.1% BSA PBS(+)) and the cells are suspended in 100 µl of the BSA solution containing the primary antibody. After allowing the suspension to react under ice cooling for 30 minutes, the cells are washed with the above-mentioned BSA solution 2 times or so. Further, in 100 µl of a BSA solution containing 1 µl of FITC-labeled secondary antibody against the primary antibody, the cells are left to stand for 30 minutes under ice cooling for reaction. The cells are washed with a BSA solution once and those cells which show strong fluorescence are detected by using a flow cytometer (FACScalibur: manufactured by Becton Dickinson). Cells showing strong fluorescence, for example, 5% of the total cells, are selected by a cell sorter and plasmid DNA is extracted therefrom. The extraction of plasmid DNA from the host cells is performed by a conventional method.
    (4) Sorting of SAT-1 cDNA and obtaining of cDNA
    The plasmid DNA obtained by the above-described operation is transfected to a suitable host cell line and the procedure of immuno-staining with the anti-GM3 antibody and recovery of strong fluorescence-showing cells in an amount of 5% of the total cells by using a flow cytometer, for example, is repeated twice or more to enrich the target cDNA by sorting. The host cell used for the sorting is preferably cultivated mammalian cells, of which 3LL-HK46 is particularly preferred. The vector to be used is not limited particularly and any expression vectors for mammalian cells may be used, but pCEV18 is preferred. The above-mentioned vector holding the target cDNA enriched by sorting is transfected to mammalian-derived cultivated cells lacking GD3 synthesis pathway, such as 3KK-HK46, simultaneously with the expression vector made by introducing the above-mentioned human α2-8 sialyltransferase cDNA by a known method into an expression vector for mammalian cells, such as pBKCMV (manufactured by STRATAGENE CO.) and detection by immuno-staining and a flow cytometer is conducted in the same manner as described above to obtain cells that show strong fluorescence in an amount of 5% of the total cells. From these cells is extracted plasmid DNA by a conventional method. The cDNA excised by a conventional method from the plasmid DNA is used to transform E. coli DH10B (manufactured by GIBCO CO.) therewith, and the transfected E. coli cells are inoculated so that 100 colonies per well can be formed, followed by sib selection to finally obtain a clone, pCEV4C7, containing an insert (4C7) of about 2.1 kbp.
    (5) Determination of the nucleotide sequence of cDNA 4C7 encoding SAT-1
    The nucleotide sequence of the cDNA obtained as described above, as is or after subcloning in a suitable plasmid such as pCRII, is determined by a conventional method.
    The nucleotide sequence of the SAT-1-encoding cDNA determined as described above and amino acid sequence deduced from the nucleotide sequence are shown by SEQ ID NO: 1 and the amino acid sequence alone is shown by SEQ ID NO: 2.
    Further, the DNA encoding the polypeptide of SAT-1 which lacks a transmembrane domain, i.e., which is in the form of solubilized protein can be obtained as follows. Namely, based on the nucleotide sequence shown by SEQ ID NO: 1 is prepared a primer selected to have a truncated form at the N-terminal side of the polypeptide of the enzyme, and the target DNA is amplified by a PCR method using the cDNA of cloned SAT-1 as a template. For example, when a DNA encoding the polypeptide of a truncated form that lacks 37 amino acid residues at the N-terminal is to be obtained, an oligonucleotide primer is synthesized based on the nucleotide sequence existing at the 3'- and 5'-terminals of the target nucleotide sequence, for example. An oligonucleotide primers having nucleotide sequences are shown by SEQ ID NO: 3 and SEQ ID NO: 4, respectively, for example, may be used as 5'- and 3'- primers, respectively, in order to perform PCR. Then, the target DNA can be obtained from the amplified PCR product, after purification, if desired.
    [3] Polypeptide comprising the whole or part of SAT-1 polypeptide encoded by the nucleotide sequence of the DNA of the present invention
    The present invention provides polypeptides which comprise the whole or part or the above-mentioned SAT-1 polypeptide encoded by the DNA of the present invention. The "part" of the polypeptide as used herein means a part which has a kind of activity or function such as having sialyltransferase-1 activity or having antigenicity. The polypeptide may be single or fused with one or more other polypeptides. The polypeptide may also lack a transmembrane domain.
    The polypeptide may be with or without a sugar chain. The kind of sugar chain is not limited particularly.
    Such a polypeptide can be obtained by, for example, the production method as described below. Determination of presence or absence of the above-mentioned activity or function can be practiced by changing the cDNA to be introduced into host cells and the substrate for tne enzyme in the assay of enzyme activity as described in JP-A 7-327678 and can be performed with ease by one skilled in the art based on, for example, the method described herein specifically.
    [4] Production method for SAT-1 polypeptide utilizing the DNA of the present invention
    The SAT-1 polypeptide can be produced by cultivating cells transformed with the above-mentioned DNA of the present invention in a suitable medium, allowing the cells to produce and accumulate in the culture the polypeptide encoded by the DNA of the present invention, and collecting the SAT-1 polypeptide from the culture.
    The cells transformed with the DNA of the present invention can be obtained by inserting a fragment of the DNA of the present invention into a known expression vector to construct a recombinant plasmid and conducting transformation with the recombinant plasmid. Examples of the cells which can be used include prokaryotic cells such as E. coli and eukaryotic cells such as mammalian cells. When prokaryotic cells such as E. coli are used, there occurs no addition of sugar chain to the SAT-1 polypeptide to be produced by the expression of the DNA of the present invention and, hence, pure SAT-1 polypeptide can be obtained. On the other hand, when eukaryotic cells such as mammalian cells are used, addition of sugar chain(s) to the SAT-1 polypeptide produced by the expression of the DNA of the present invention occurs. Therefore, polypeptides can be obtained in the same form as ordinary SAT-1 which contains also a sugar chain.
    In this production method, a host-vector-system usually used in the production of proteins may be used. While it is preferred to use a combination of mammalian-derived cultivated cell, such as 3LL-HK46 cell, 3LL-ST28 cell or COS-1 cell, and an expression vector for mammalian cells, such as pCEV18, pME18S (Maruyama et al., Med. Immunol., 20, 27 (1990)), the present invention is not limited thereto. The medium and cultivation conditions may be selected suitably depending on the host cell to be used.
    While the DNA of the present invention may be expressed over the whole length thereof, it may be suppressed as a fused polypeptide with another polypeptide. Also, a part of the DNA of the present invention may be expressed as a partial polypeptide.
    A specific example of construction of recombinant plasmid which expresses the above-mentioned fused polypeptide is by the following method. Namely, the DNA of the present invention is incorporated into a vector constructed so that a gene introduced into a plasmid such as pGIR201protA (Kitagawa, H. and Paulson, J. C., J. Biol. Chem., 269, 1394-1401 (1994)) can be expressed as a fused protein by a conventional method to construct a vector having genes for plural proteins on the same reading frame. Then, from the vector is excised NheI fragment, which encodes a fused protein, and the fragment is ligated to a suitable vector such as pCEV18 by the same operation as described above.
    The polypeptide of the present invention can be collected from the culture by a known purification method for polypeptides. Specifically, there can be used affinity chromatography using a Sepharose column to which lactosylceramide or CMP-sialic acid, for example is bonded. When the DNA of the present invention is expressed as a fused polypeptide, the culture of the host cell can be purified by affinity chromatography using a column to which a substance is bonded having high affinity for the polypeptide fused with SAT-1, such as antibody, in addition to the above-mentioned affinity column. For example, a linker having an amino acid sequence which a specified proteolytic enzyme can recognize and cleave may be incorporated in advance between the SAT-1 and the polypeptide of other protein in the fused polypeptide. This allows the cleavage to occur at the linker site of the fused polypeptide after purification thereof so that SAT-1, whose purification has been difficult heretofore can be obtained. The combination of the specified proteolytic enzyme and the specified sequence which the enzyme recognizes is, for example, a combination of signal peptidase which acts upon the synthesis of proinsulin and signal peptide of insulin. The above-mentioned culture includes a medium and cells in the medium.
    The activity of sialyltransferase can be assayed by changing the substrate for the enzyme in a conventional assay method for assaying general ganglioside synthesis (JP-A 7-327678). For example, a suitable amount of the culture or the enzyme purified by the above-described method is added to a reaction mixture containing 100 mM sodium cacodylate, 10 mM manganese chloride, 0.2 mM CMP-radioactive substance-labeled sialic acid, 0.4 mM lactosylceramide, and 0.3% Triton CF-54. The mixture is adjusted to pH 6.5 and incubated at 37°C for 2 hours and the reaction product is developed by a conventional thin layer chromatography and the enzyme activity is determined by using Fujix BAS2000 Bio Imaging Analyzer (manufactured by Fuji Photo Film Co., Ltd.).
    EXAMPLES
    The present invention will be described in further detail by examples. However, the present invention is not limited thereto without exceeding the object of the present invention.
    (1) Differentiation induction of HL-60 cell and construction of cDNA
    HL-60 cells were cultivated in RPMI-1640 (manufactured by NISSUI PHARM. CO.) containing 24 nM TPA under the conditions of 5 vol% CO2 and 95 vol% air at 37°C for 48 hours to induce differentiation. The cultivated cells were collected by centrifugation at 1000×g and total RNA was prepared from the collected cells by guanidine thiocyanate-acid-phenol-chloroform method (AGPC method). From differentiated 5×106 cells was obtained about 40 µg of RNA. From the RNA, poly(A)+RNA was purified by oligo-(dT) cellulose column chromatography.
    The poly(A)+RNA was used as a template for reverse transcription reaction to construct a primary strand of DNA, and the DNA in turn was used for synthesizing double-stranded cDNA (Gubber, V. and Hoffman, B. J., Gene, 25, 283 (1983)).
    To the double-stranded cDNA was ligated a restriction enzyme BSTX1 adapter and the ligate was introduced into the BSTX1 site of pCEV18 to construct a cDNA library.
    (2) Transfection of cDNA to 3LL-HK46 cells
    The above-mentioned cDNA library was introduced into 3LL-HK46 cells by using an electroporation method and the transfected cells were cultivated for 48 hours under the conditions of 5 vol% CO2 and 95 vol% air at 37°C.
    (3) Detection of host cells expressing ganglioside and preparation of cDNA
    The 3LL-HK46 cells after the cultivation were immuno-stained with M2590, anti-GM3 antibody, and with FITC-labeled rabbit anti-murine IgG antibody. The stained cells were passed through a flow cytometer (FACScalibur) to detect fluorescence-positive cells. 5% of the cells on the positive side were collected and plasmid DNA was prepared therefrom. Then, the procedures of introduction of cDNA into 3LL-HK46 cells by electroporation, 48-hour cultivation of the transfected cells, immuno-staining, and detection and collection by using a flow cytometer were further repeated twice.
    The plasmids finally obtained by this method were introduced into 3LL-HK46 cells together with pBKCMV GD3 (a plasmid obtained by introducing the cDNA of human α2-8 sialyltransferase (GD3 synthase) to pBKCMV plasmid vector manufactured by STRATAGENE CO.). After cultivating them for 48 hours, the resulting cells were immuno-stained with R24, anti-GD3 antibody, and with FITC-labeled rabbit anti-murine IgG antibody, and 5% of the total cells which show strong fluorescence were detected by a flow cytometer and collected.
    From these cells was prepared plasmid DNA, which then was transfected to E. coli DH10B (manufactured by GIBCO) by electroporation. After repeating the transfection and screening with ampicillin twice, positive colonies were dispensed to each well in a 96-well microplate in an amount of 100 colonies per well. Nine (9) microplates were inoculated with the transfected cells and only one well was selected by sib selection. Then, 2,400 colonies derived from this single well were extended to twenty five (25) 96-well microplates in a population of 1 colony per well and further sib selection gave rise to a positive clone (pCEV4C7). The pCEV4C7 thus obtained was expressed in 3LL-HK46 cells temporarily and flow cytometry analysis was performed using anti-GM3 antibody (M2590) in the same manner as described above. 3LL-HK46 cells temporarily expressing pCEV18, as a control, did not express GM3 on the cell membrane whereas 3LL-HK46 cells temporarily expressing pCEV4C7 expressed GM3 on the cell membrane and fluorescence was detected.
    (4) Determination of nucleotide sequence
    The nucleotide sequence of double-stranded DNA of pCEV4C7 was determined by a dideoxy chain termination method using an autocycle sequencing kit (manufactured by PHARMACIA CO.) and Pharmacia A.L.F. DNA sequencer (manufactured by PHARMACIA CO.). The nucleotide sequence thus determined and an amino acid sequence deduced therefrom are shown by SEQ ID NO: 1 and the amino acid sequence alone is shown by SEQ ID NO: 2. The cDNA insert 4C7 which is contained in pCEV4C7 is of about 2.1 kbp and is revealed to encode a protein (molecular weight 41,244 Da containing 359 amino acid residues starting with a nucleotide at 202 position as a translation initiation point. Fig. 1 is a schematic view which illustrates the structure expected from the amino acid sequence. As a result of hydropathy plot analysis, the amino acid sequence was revealed to correspond to a type-2 membrane protein in which the transmembrane domain (TM in Fig. 1) exists in the region of the 16th to 29th amino acid residues on the N-terminals. Search of this sequence with gene data base in GenBank showed no high homology with any of the data therein. However, with regard to the sialyl motifs (L and S) in the sialyltransferase homologous region existing in the central part and C-terminal region of the sequence for sialyltransferase, relatively high homology was recognized although some substitution was observed (Fig. 2). The sialyltransferases used for comparison were eleven (11) species, i.e., h2,3ST (JP-A 5-336963), rSTX (J. Biol. Chem., 268, 11504-11507 (1993)), rST3N-1 (J. Biol. Chem., 267, 21011-21019 (1992)), hST3N-2 (J. Biol. Chem., 268, 22782-22787 (1993)), pST30-1 (J. Biol. Chem., 276, 21004-21010 (1992)), mST30-2 (Eur. J. Biochem., 216, 377-385 (1993)), mST4' (NCBI Seq. ID 558532), hSAT4(a) (Gycbiology, 5, 319-325 (1995)), hST6N (Nuc. Acids Res., 18, 667 (1990)), rST6N (J. Biol. Chem., 262, 17735-17743 (1987)), h2,8ST (JP-A 7-327678). The results suggest that SAT-1 which is encoded by the insert 4C7 in pCEV4C7 belongs to the sialyltransferase family. Further, the amino acid sequence indicates existence of four consensus sequences of the N-glycosylation site (Δ in Fig. 1), whereas the two sites thereof on the N-terminal side exist near the transmembrane domain and in the sialyl motifs so that these two N-terminal side sites could be less N-glycosylated as compared with the two sites on the C-terminal side.
    (5) GM3 synthesis in cells expressing SAT-1 cDNA
    pEV4C7 obtained by incorporating the above-mentioned SAT-1-encoding cDNA (4C7) into expression vector pCEV18 was transfected to 3LL-HK46 cells by an electroporation method and the GM3 synthase activity of the cells after 48-hour cultivation was assayed by the following method. Namely, 20 µl of a reaction mixture (pH 6.5) containing 0.1 mM CMP-(14C)-sialic acid (2×103 CPM), 0.4 mM lactosylceramide, 0.3% (W/V) Triton CF-54, 10 mM MgCl2, 100 mM sodium cacodylate, 150 µg of the homogenate of 3LL-HK46 cells to which pCEV4C7 was incorporated, and 1 mM sialidase inhibitor (2,3-dehydro-2-deoxy-N-acetylsial ic acid (2,3-dehydro-2-deoxy-NeuAc, manufactured by BOEHRINGER MANNHEIM GMBH) was incubated at 37°C for 2 hours and then 10 µl of methanol was added thereto to stop the reaction. 8 µl of the reaction mixture was charged on a C18 reversed phase thin layer chromatography place (RP-18W HPTLC plate, manufactured by MERCK Co.) and developed with water for 10 minutes. Radioactive substance-labeled reaction products were scrubbed from the original point and GM3 was collected therefrom by extraction with 300 µl of chloroform/methanol (1:1, V/V). After the extracts were concentrated to dryness, they were charged on a 60HPTLC plate (manufactured by MERCK CO.) for silica gel thin layer chromatography. After development with chloroform/methanol/0.5% aqueous CaCl2 solution (55:45:10:, V/V/V), the layer was treated with orcinol sulfate to develop color and measured of radioactivity incorporated into ganglioside using Fujix BAS2000 Bio Imaging Analyzer (manufactured by FUJI PHOTO FILM CO., LTD.). The results revealed uptake of 14C by ganglioside GM3 and GM3 synthesis by SAT-1 was detected in the SAT-1 cDNA-transfected cells.
    The GM3 synthase activity was high at pH 6.0 to 7.0, particularly at around pH 6.5 and increased at least 1.5 times in the presence of 10 mM of Mn2+.
    Annex to the description
    Figure 00390001
    Figure 00400001
    Figure 00410001
    Figure 00420001
    Figure 00430001
    Figure 00440001

    Claims (15)

    1. A sialyltransferase having the following physico-chemical properties:
      (1) Activity:
         transfers sialic acid from a sialic acid donor selectively to a 3-hydroxyl group of a galactose residue contained in lactosylceramide as a sialic acid acceptor to produce ganglioside GM3;
      (2) Optimal reaction pH:
         6.0 to 7.0; and
      (3) Activation:
         the activity increases at least 1.5 times with 10 mM of Mn2+ as compared with the case in the absence thereof.
    2. A sialyltransferase having an amino acid sequence shown by SEQ ID NO: 5 on C-terminal of the amino acid sequence thereof, and having the physico-chemical property:
      (1) Activity:
         transfers sialic acid from a sialic acid donor selectively to a 3-hydroxyl group of a galactose residue contained in lactosylceramide as a sialic acid acceptor to produce ganglioside GM3.
    3. A sialyltransferase having an amino acid sequence comprising an amino acid sequence shown by SEQ ID NO: 6, and having the physico-chemical property:
      (1) Activity:
         transfers sialic acid from a sialic acid donor selectively to a 3-hydroxyl group of a galactose residue contained in lactosylceramide as a sialic acid acceptor to produce ganglioside GM3.
    4. The sialyltransferase according to any one of claims 1 to 3, wherein said sialic acid donor is cytidine 5-monophosphate-sialic acid (CMP-sialic acid).
    5. The sialyltransferase according to any one of claims 1 to 4, wherein said sialyltransferase is derived from human.
    6. A sialyltransferase comprising a polypeptide having an amino acid sequence selected from the group consisting of:
      (a) an amino acid sequence shown by SEQ ID NO: 2, and
      (b) an amino acid sequence shown by SEQ ID NO: 2, which has therein substitution, deletion, insertion or rearrangement of one or a few amino acid residues, said sialyltransferase having an enzyme activity of transferring sialic acid from a sialic acid donor selectively to a 3-hydroxyl group of a galactose residue contained in lactosylceramide as a sialic acid acceptor to produce ganglioside GM3.
    7. A sialyltransferase comprising a polypeptide, wherein said polypeptide having an amino acid sequence which has not less than 65% of homology with an amino acid sequence shown by SEQ ID NO: 2.
    8. A sialyltransferase having no transmembrane domain, and said sialyltransferase having an enzyme activity of transferring sialic acid from a sialic acid donor selectively to a 3-hydroxyl group of a galactose residue contained in lactosylceramide as a sialic acid acceptor to produce ganglioside GM3.
    9. The sialyltransferase according to claim 8, wherein said sialyltransferase having an amino acid sequence which is defective in a transmembrane domain sequence from an amino acid sequence shown by SEQ ID NO: 2.
    10. A sialyltransferase having the amino acid sequence of amino acid numbers 38 to 358 in an amino acid sequence shown by SEQ ID NO: 2.
    11. A DNA encoding all or a sialyltransferase-active part of the polypeptide of the sialyltransferase as defined in claim 6.
    12. A DNA which has a nucleotide sequence shown by SEQ ID NO: 1.
    13. A DNA which has a nucleotide sequence of base numbers 202 to 1278 in a nucleotide sequence shown by SEQ ID NO: 1.
    14. A DNA which hybridizes with a polynucleotide having a nucleotide sequence complementary to a nucleotide sequence shown by SEQ ID NO: 1 under stringent conditions.
    15. A DNA which hybridizes with a polynucleotide having a nucleotide sequence complementary to a nucleotide sequence of base numbers 202 to 1278 in the nucleotide sequence shown by SEQ ID NO: 1.
    EP98305422A 1997-07-09 1998-07-08 Sialyltransferase and DNA encoding the same Withdrawn EP0890645A3 (en)

    Applications Claiming Priority (3)

    Application Number Priority Date Filing Date Title
    JP184184/97 1997-07-09
    JP18418497 1997-07-09
    JP9184184A JPH1118778A (en) 1997-07-09 1997-07-09 Sialic acid transferase and dna encoding the same

    Publications (2)

    Publication Number Publication Date
    EP0890645A2 true EP0890645A2 (en) 1999-01-13
    EP0890645A3 EP0890645A3 (en) 2000-08-30

    Family

    ID=16148840

    Family Applications (1)

    Application Number Title Priority Date Filing Date
    EP98305422A Withdrawn EP0890645A3 (en) 1997-07-09 1998-07-08 Sialyltransferase and DNA encoding the same

    Country Status (2)

    Country Link
    EP (1) EP0890645A3 (en)
    JP (1) JPH1118778A (en)

    Cited By (3)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    WO2001055410A2 (en) * 2000-01-28 2001-08-02 Musc Foundation For Research Development Ceramidase compositions and methods based thereon
    US6280989B1 (en) 1999-06-17 2001-08-28 Dmitri Kapitonov Sialyltransferases
    WO2006028241A1 (en) * 2004-09-08 2006-03-16 Takeda Pharmaceutical Company Limited Preventive/therapeutic drug for arteriosclerosis

    Families Citing this family (1)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    EP1726313A4 (en) * 2004-01-16 2008-04-09 Takeda Pharmaceutical Drug for preventing and treating arteriosclerosis

    Citations (2)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    WO1995004816A1 (en) * 1993-08-04 1995-02-16 The Regents Of The University Of California Compositions and methods for producing sialyltransferases
    WO1998042738A1 (en) * 1997-03-21 1998-10-01 Human Genome Sciences, Inc. 87 human secreted proteins

    Patent Citations (2)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    WO1995004816A1 (en) * 1993-08-04 1995-02-16 The Regents Of The University Of California Compositions and methods for producing sialyltransferases
    WO1998042738A1 (en) * 1997-03-21 1998-10-01 Human Genome Sciences, Inc. 87 human secreted proteins

    Non-Patent Citations (2)

    * Cited by examiner, † Cited by third party
    Title
    MELKERSON-WATSON L J ET AL: "PURIFICATION TO APPARENT HOMOGENEITY BY IMMUNOAFFINITY CHROMATOGRAPHY AND PARTIAL CHARACTERIZATION OF THE G-M-3 GANGLIOSIDE-FORMING ENZYME CMP-SIALIC ACID LACTOSYLCERAMIDE ALPHA-2 3 SIALYLTRANSFERASE SAT-1 FROM RAT LIVER GOLGI" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 7, 1991, pages 4448-4457, XP002141346 ISSN: 0021-9258 *
    PREUSS UTE ET AL: "Purification and characterization of CMP-N-acetylneuraminic acid:Lactosylceramide (alpha-2-3) sialyltransferase (G-M3-synthase) from rat brain." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 35, 1993, pages 26273-26278, XP002141345 ISSN: 0021-9258 *

    Cited By (4)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US6280989B1 (en) 1999-06-17 2001-08-28 Dmitri Kapitonov Sialyltransferases
    WO2001055410A2 (en) * 2000-01-28 2001-08-02 Musc Foundation For Research Development Ceramidase compositions and methods based thereon
    WO2001055410A3 (en) * 2000-01-28 2002-03-14 Musc Found For Res Dev Ceramidase compositions and methods based thereon
    WO2006028241A1 (en) * 2004-09-08 2006-03-16 Takeda Pharmaceutical Company Limited Preventive/therapeutic drug for arteriosclerosis

    Also Published As

    Publication number Publication date
    EP0890645A3 (en) 2000-08-30
    JPH1118778A (en) 1999-01-26

    Similar Documents

    Publication Publication Date Title
    US8202705B2 (en) Sialyltransferase and DNA encoding the same
    Kukowska-Latallo et al. A cloned human cDNA determines expression of a mouse stage-specific embryonic antigen and the Lewis blood group alpha (1, 3/1, 4) fucosyltransferase.
    Henion et al. Defining the minimal size of catalytically active primate α1, 3 galactosyltransferase: structure-function studies on the recombinant truncated enzyme
    EP0552470B1 (en) alpha 2-3 Sialyltransferase
    Schachter Enzymes associated with glycosylation
    Ishida et al. Molecular cloning and functional expression of the human Golgi UDP-N-acetylglucosamine transporter
    US7476730B2 (en) Sulfotransferase and DNA encoding the enzyme
    WO2001046400A1 (en) MODIFIED α-1,2-FUCOSYLTRANSFERASE GENE AND PROCESS FOR PRODUCING α-1,2-FUCOSYLTRANSFERASE AND FUCOSE-CONTAINING SUGAR CHAIN
    EP2905341B1 (en) Methods for producing GDP-fucose using nucleotide sugar transporters and recombinant microorganism host cells used therefor
    US8030043B2 (en) β-galactoside-α2,3-sialyltransferase, a gene encoding thereof, and a method for producing thereof
    US6218161B1 (en) Sugar-chain synthetase and process for producing the same
    JP2810635B2 (en) New sugar chain synthase
    US6783966B1 (en) Alpha1, 4-galactosyltransferase and DNA encoding thereof
    EP0890645A2 (en) Sialyltransferase and DNA encoding the same
    EP2006378A1 (en) Novel beta-galactoside alpha- 2,6-sialyltransferase, gene coding for the transferase and process for producing the same
    Narimatsu Recent progress in molecular cloning of glycosyltransferase genes of eukaryotes
    US6040156A (en) DNA encoding glucuronyltransferase
    JP4101976B2 (en) Human-derived sialyltransferase and DNA encoding the same
    EP1876234B1 (en) Beta-galactoside-alpha2,3-sialyltransferase, gene encoding the same, and process for production of the same
    JP2001521399A (en) DNA sequence encoding mammalian glucuronyl C5-epimerase and method for producing the same
    JP2006314320A (en) Sialic acid transferase and dna encoding the same
    JP4629214B2 (en) N-acetylglucosamine transferase
    JP4377987B2 (en) Galactose transferase and DNA encoding the same
    US20230313248A1 (en) Synthesis of c-glycosides of interest
    WO2001077337A1 (en) α1,4-N-ACETYLGALACTOSAMINE TRANSFERASE GENE AND PROCESS FOR PRODUCING THIS ENZYME AND N-ACETYLGALACTOSAMINE-CONTAINING COMPLEX CARBOHYDRATE

    Legal Events

    Date Code Title Description
    PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

    Free format text: ORIGINAL CODE: 0009012

    AK Designated contracting states

    Kind code of ref document: A2

    Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    AX Request for extension of the european patent

    Free format text: AL;LT;LV;MK;RO;SI

    PUAL Search report despatched

    Free format text: ORIGINAL CODE: 0009013

    AK Designated contracting states

    Kind code of ref document: A3

    Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    AX Request for extension of the european patent

    Free format text: AL;LT;LV;MK;RO;SI

    AKX Designation fees paid
    STAA Information on the status of an ep patent application or granted ep patent

    Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

    18D Application deemed to be withdrawn

    Effective date: 20010301

    REG Reference to a national code

    Ref country code: DE

    Ref legal event code: 8566